Treatment Options for Tardive Dyskinesia

Author(s):

Jason Noel, PharmD, MPA, BCPP,Julie Dopheide, PharmD, BCPP, FASHP

Panelists discuss how VMAT2 inhibitors deutetrabenazine and valbenazine have revolutionized TD treatment through their proven efficacy in reducing involuntary movements and favorable safety profiles, with clinical trials demonstrating significant symptom improvement as measured by AIMS scores while maintaining psychiatric stability and showing key differences in dosing schedules and titration approaches.

EP: 1.Optimizing Tardive Dyskinesia Care: Strategies to Advance Treatment Approaches

EP: 2.Diagnosing Tardive Dyskinesia

EP: 3.Impact of Tardive Dyskinesia on Quality of Life

EP: 4.Improving Outcomes Through Patient Education and Addressing Unmet Needs

Now Viewing

EP: 5.Treatment Options for Tardive Dyskinesia

EP: 6.Long-Term Outcomes with VMAT2 Inhibitors

EP: 7.Safety Profile of VMAT2 Inhibitors and Impact on Treatment Selection

EP: 8.Management of Tardive Dyskinesia and Comorbidities

EP: 9.Shared Decision-Making in Tardive Dyskinesia

EP: 10.Strategies for Optimizing Therapy

EP: 11.Patient Journey and the Role of the Pharmacist

EP: 12.Patient Counseling and Management of Adverse Events

EP: 13.Dosing and Titration Considerations

EP: 14.Enhancing Adherence and Collaborative Care

EP: 15.Educational Resources to Support Patients

Video series above is prompted by the following:

Please provide an overview of the pharmacological treatment options currently available for patients with TD, highlighting their safety and efficacy.
Deutetrabenazine
Valbenazine